Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
BMRN Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: May 07, 2026
Report Source: 2026 1st Quarter Report
BioMarin Pharmaceutical Inc. Stock Analysis BMRN
United States Health Care Large Cap Report: BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.
Read More BioMarin Pharmaceutical Inc (BMRN) Chart
Key Statistics of BioMarin Pharmaceutical Inc (BMRN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$55.80Volume
2.03MP/E Ratio (TTM)
31.1552 Week Range
Market Cap
10.46BAvg. Volume
2.26MDividend Yield
-Financial Metrics & Statements of BioMarin Pharmaceutical Inc (BMRN)
FAQ's for BioMarin Pharmaceutical Inc (BMRN)
- According to Musaffa’s Shariah screening methodology, BioMarin Pharmaceutical Inc (BMRN) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes BioMarin Pharmaceutical Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in BioMarin Pharmaceutical Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of BioMarin Pharmaceutical Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of BioMarin Pharmaceutical Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of BioMarin Pharmaceutical Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.